Hubbry Logo
TBX21TBX21Main
Open search
TBX21
Community hub
TBX21
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
TBX21
TBX21
TBX21
View on Wikipedia
from Wikipedia

TBX21
Identifiers
AliasesTBX21, T-PET, T-bet, TBET, TBLYM, T-box 21, T-box transcription factor 21, IMD88
External IDsOMIM: 604895; MGI: 1888984; HomoloGene: 8353; GeneCards: TBX21; OMA:TBX21 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

30009

57765

Ensembl

ENSG00000073861

ENSMUSG00000001444

UniProt

Q9UL17

Q9JKD8

RefSeq (mRNA)

NM_013351

NM_019507

RefSeq (protein)

NP_037483

NP_062380

Location (UCSC)Chr 17: 47.73 – 47.75 MbChr 11: 96.99 – 97.01 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

T-box transcription factor TBX21, also called T-bet (T-box expressed in T cells), is a protein that in humans is encoded by the TBX21 gene.[5] Though being for long thought of only as a master regulator of type 1 immune response, T-bet has recently been shown to be implicated in development of various immune cell subsets and maintenance of mucosal homeostasis.[6]

Function

[edit]

This gene is a member of a phylogenetically conserved family of genes that share a common DNA-binding domain, the T-box. T-box genes encode transcription factors involved in the regulation of developmental processes. This gene is the human ortholog of mouse Tbx21/Tbet gene. Studies in mouse show that Tbx21 protein is a Th1 cell-specific transcription factor that controls the expression of the hallmark Th1 cytokine, interferon-gamma (IFNg). Expression of the human ortholog also correlates with IFNg expression in Th1 and natural killer cells, suggesting a role for this gene in initiating Th1 lineage development from naive Th precursor cells.[5]

The function of T-bet is best known in T helper cells (Th cells). In naïve Th cells the gene is not constitutively expressed, but can be induced via 2 independent signalling pathways, IFNg-STAT1 and IL-12-STAT4 pathways. Both need to cooperate to reach stable Th1 phenotype. Th1 phenotype is also stabilised by repression of regulators of other Th cell phenotypes (Th2 and Th17). In a typical scenario it is thought that IFNg and T cell receptor (TCR) signalling initiates the expression of Tbet, and once TCR signalling stops, signalling via IL-12 receptor can come to play as it was blocked by repression of expression of one of its receptor subunits (IL12Rb2) by TCR signalling. IL-2 signalling enhances the expression of IL-12R. The 2-step expression of T-bet can be viewed as a safety mechanism of sort, which ensures, that cells commit to the Th1 phenotype only when desired.[6]

T-bet controls transcription of many genes, for example proinflammatory cytokines like lymphotoxin-a, tumour necrosis factor and ifng, which is a hallmark cytokine of type one immunity.[7][6] Certain chemokines are also regulated by T-bet, namely xcl1, ccl3, ccl4 and chemokine receptors cxcr3, ccr5. The expression of T-bet controlled genes is facilitated by 2 distinct mechanisms: chromatin remodelation via enzyme recruitment and direct binding to enhancer sequences promoting transcription or 3D gene structure supporting transcription. T-bet also recruits other transcription factors like HLX, RUNX1, RUNX3 which aid it in setting Th1 transcription profile.[6]

Apart from promoting type 1 immune response (Th1), T-bet also suppresses the other types of immune response. Type 2 immune response (Th2) phenotype is repressed by sequestering of its master regulator, GATA3 away from its target genes. Gata3 expression is further silenced by promotion of silencing epigenetic changes in its region. In addition to that the Th2 specific cytokines are also silenced by binding of T-bet and RUNX3 to il4 silencer region. Type 17 immune response (Th17) phenotype is suppressed by RUNX1 recruitment, which disallows it to mediate Th17 specific genes, like rorc, a Th17 master regulator. Rorc is also silenced by epigenetic changes promoted by T-bet and STAT4.[6]

T-bet also performs function in cytotoxic T cells and B cells. In cytotoxic T cells it promotes IFNg, granzyme B expression and in cooperation with another transcription factor EOMES their maturation. The role of T-bet in B cells seems to be to direct the cell towards type 1 immune response expression profile, which involves secretion of antibodies IGg1 and IGg3 and is usually elevated during viral infections. These populations of B cells differ from standard ones by their lack of receptors CD21 and CD27, also given that these cells have undergone antibody class switch, they are regarded as memory B cells. These cells have been shown to secrete IFNg and in vitro to polarise naïve T helper cells towards Th1 phenotype. Populations of T-bet positive B cells were also identified in various autoimmune diseases like systemic lupus erythematosus, Crohn's disease, multiple sclerosis and rheumatoid arthritis.[8]

Role in mucosal homeostasis

[edit]

It has been identified that T-bet contributes to the maintenance of mucosal homeostasis and mucosal immune response. Mice lacking adapative immune cells and T-bet (RAG -/-, T-bet -/-) developed disease similar to human ulcerative colitis (hence the name TRUC), which was later attributed to the outgrowth Gram-negative bacteria, namely Helicobacter typhlonius. The dysbiosis appears to be a consequence of multiple factors, firstly the innate lymphoid cells 1 (ILC1) population and a subset of ILC3s are missing, because the expression of T-bet is needed for their maturation. Secondly, T-bet ablation causes increased levels of TNF, as its expression is not repressed in dendritic cells and immune system is more biased away from Th1.[9]

Role in disease

[edit]

Atherosclerosis

[edit]

Atherosclerosis is an autoimmune disease caused by inflammation and associated infiltration of immune cells in fatty deposits in arteries called atherosclerosis plaques. Th1 cells are responsible for production of proinflammatory cytokines contributing to the progression of the disease by promoting expression of adhesive (e.g., ICAM1) and homing molecules (mainly CCR5) needed for cellular migration. Experimental vaccination of patients with peptides derived from apolipoprotein B, part of low-density lipoprotein, which is deposited on arterial walls, has shown increased T regulatory cells (TREGs) and cytotoxic T cells. The vaccination has showed smaller Th1 differentiation, though the mechanism behind it remains unresolved. Currently it is hypothesised that the decrease of Th1 differentiation is caused by the destruction of dendritic cells presenting auto antigens by cytotoxic T cells and increased differentiation of TREGs suppressing immune response. Taken together T-bet might serve as a potential target in treatment of atherosclerosis.[7]

Asthma

[edit]

The transcription factor encoded by TBX21 is T-bet, which regulates the development of naive T lymphocytes. Asthma is a disease of chronic inflammation, and it is known that transgenic mice born without TBX21 spontaneously develop abnormal lung function consistent with asthma. It is thought that TBX21, therefore, may play a role in the development of asthma in humans as well.[10]

Experimental autoimmune encephalomyelitis

[edit]

Initially it was thought that experimental autoimmune encephalomyelitis (EAE) is caused by autoreactive Th1 cells. T-bet-deficient mice were resistant to EAE.[11] However, later research has discovered, that not only Th1 but also Th17 and ThGM-CSF cells are the cause of immunopathology. Interestingly, IFNg, a main product of T-bet, has shown bidirectional effect in EAE. Injection of IFNg during acute stage worsens the course of the disease, presumably by strengthening Th1 response, however injection of IFNg in chronic stage has shown suppressive effect on EAE symptoms. Currently it is thought that IFNg stops T helper cells from committing for example to the Th17 phenotype, stimulates indoleamine 2,3-dioxygenase transcription (kynurenines or kyn pathway) in certain dendritic cells, stimulates cytotoxic T cells, downregulates T cell trafficking and limits their survival. T-bet and its controlled genes remain a possible target in treatment of neurological autoimmune diseases.[12]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

TBX21

View on Grokipedia
from Grokipedia
TBX21, also known as T-bet or T-box transcription factor 21, is a gene that encodes a member of the T-box family of DNA-binding s essential for orchestrating type 1 immune responses. It serves as a master regulator in the differentiation of T helper 1 (Th1) cells, driving the expression of the cytokine interferon-gamma (IFN-γ) while suppressing alternative T helper lineages such as Th2 and Th17, thereby bridging innate and adaptive immunity across multiple cell types including CD4⁺ T cells, CD8⁺ T cells, natural killer (NK) cells, B cells, and dendritic cells. The TBX21 was independently cloned in 2000 by two groups, mapping to human 17q21.32 (genomic coordinates GRCh38: 17:47,733,236-47,746,122) and encoding a 535-amino-acid protein that shares 88% identity with its mouse ortholog. Expressed prominently in immune tissues such as the , , , and peripheral blood leukocytes, as well as in NK cells and activated T cells, T-bet contains a conserved T-box domain that binds to T-box binding elements in target promoters to activate transcription. Its expression is induced by signals including T cell receptor stimulation, IL-12 via STAT4, and IFN-γ via , with autoregulatory loops enhancing its own transcription. In immune function, T-bet promotes Th1 lineage commitment by directly transactivating the IFNG gene and repressing genes associated with Th2 cytokines like IL-4 and IL-5, while also inhibiting Th17 differentiation through suppression of IL-17 production. In NK cells, it cooperates with EOMES to drive maturation, IFN-γ secretion, and anti-tumor activity, such as control of . For B cells, T-bet regulates class-switch recombination to IgG2a, enhances antiviral antibody responses, and supports formation and differentiation, particularly in chronic infections. In dendritic cells, it maintains mucosal by limiting TNF production and priming Th1 responses. Overall, T-bet coordinates resistance to intracellular pathogens like and Leishmania major by bolstering IFN-γ-mediated immunity. Dysfunction in TBX21 contributes to a spectrum of diseases reflecting its central immune role. Loss-of-function mutations, such as a homozygous deletion/insertion (c.466_471delGAGATGinsAGTTTA), cause immunodeficiency-88 (IMD88; MIM 619630), characterized by impaired IFN-γ production, recurrent infections, and disrupted Th1 and NK cell responses. Conversely, polymorphisms like the -1993T-C promoter variant increase susceptibility to and by altering Th1/Th2 balance. In autoimmunity, T-bet drives in conditions including via excessive IFN-γ, through autoreactive T cell migration, systemic lupus erythematosus by promoting IgG2a autoantibodies, and by enhancing Th1/Th17 responses. T-bet knockout mice exhibit asthma-like airway hyperreactivity, heightened infection vulnerability, and dysregulated B cell switching, underscoring its protective yet double-edged role. Emerging links connect TBX21 overexpression in leukocytes to late-onset and , potentially via chronic .

Gene and Protein Overview

Gene Structure and Location

The TBX21 gene is located on the long arm of human chromosome 17 at the q21.32 cytogenetic band, with genomic coordinates spanning 47,733,236 to 47,746,122 bp on the forward strand according to the GRCh38.p14 assembly. This positions the gene within a region associated with immune-related traits, though specific disease linkages are explored elsewhere. The gene consists of 6 exons distributed over approximately 13 kb of genomic DNA, with the canonical transcript ENST00000177694 encoding the full-length protein. Exon 1 includes the translation start codon (ATG) and encompasses both 5' untranslated and initial coding sequences, while subsequent exons contain the majority of the coding region, including the conserved T-box domain; the transcript totals 2,583 bp with a coding sequence of 1,608 bp. TBX21 exhibits strong evolutionary conservation across vertebrates, reflecting its in immune development, with orthologs identified in over 290 including mammals, birds, and . The T-box shows 100% sequence identity between and orthologs (Tbx21), while the overall protein shares about 88% identity, underscoring functional preservation in mammalian Th1 responses. Common genetic variants in TBX21 include the nonsynonymous polymorphism rs2240017 (c.99G>A, p.His33Gln) in exon 1, which has been linked to altered transcriptional activity and enhanced responsiveness to corticosteroids in patients by modulating Th1 differentiation. This variant exemplifies how single changes in TBX21 can influence immune regulation, with the varying across populations (e.g., ~20% in Europeans).

Protein Structure and Mechanism

The T-bet protein, encoded by the TBX21 , is a 535-amino-acid polypeptide with a calculated molecular weight of approximately 58 kDa. It belongs to the T-box family of transcription factors and possesses a modular essential for its regulatory functions. The N-terminal region (residues 1–200) contains a that recruits co-activators to initiate . The central T-box spans residues 136–327 and is highly conserved across , enabling specific recognition of DNA target sites. The C-terminal region functions as a repression domain, facilitating the suppression of alternative transcriptional programs through interactions with chromatin-modifying complexes. This domain organization allows T-bet to both activate and repress genes in a context-dependent manner. The T-box domain confers high specificity to T-bet by binding to T-half sites with the consensus sequence AGGTGTGA, often as palindromic elements that support dimerization. Structural studies reveal that the domain forms a compact fold with α-helices inserting into the DNA minor groove, achieving a dissociation constant (K_d) of approximately 19 nM for optimal sites and promoting stable, long-lived complexes via slow off-rates. This binding architecture not only ensures precise genomic targeting but also enables T-bet dimers to bridge distant DNA elements, facilitating chromatin looping between enhancers and promoters. As a , T-bet drives by directly binding to the promoter and enhancers of the IFN-γ gene (IFNG), thereby promoting its transcription in immune cells. It cooperates with co-factors such as Runx1 to enhance activation of Th1-specific genes and with NFAT (NFATC2) to modulate cytokine responses, where phosphorylation at Thr-303 is required for NFAT interaction and promoter binding. Additionally, T-bet interacts with Runx3 to repress opposing lineages like Th2 and Th17. Post-translational modifications fine-tune T-bet's activity and localization. at multiple serine and threonine residues, including sites regulated by (e.g., Ser-53, Ser-225, Ser-513), modulates its transcriptional potency, while ERK signaling contributes to through serine that enhances DNA binding and co-factor recruitment. Ubiquitination at Lys-313 targets T-bet for proteasomal degradation, and its inhibition promotes nuclear accumulation and sustained activity; sumoylation further influences stability and localization, competing with ubiquitination to regulate nuclear retention. These modifications ensure dynamic control of T-bet's function in response to cellular signals.

Expression and Regulation

Cellular and Tissue Expression

TBX21, encoding the T-bet, exhibits selective expression primarily within immune cells of the adaptive and innate lineages. It is highly expressed in CD4+ T helper 1 (Th1) cells, where it serves as a master regulator of differentiation, as well as in + cytotoxic T cells and natural killer (NK) cells, promoting their effector functions. Expression is also prominent in γδ T cells, contributing to their IFN-γ production, while it can be induced in dendritic cells and B cells upon stimulation with cytokines like IFN-γ or agonists. In single-cell sequencing data from immune compartments, TBX21 shows enrichment in these cytotoxic and innate-like populations, with relative expression levels up to 22.8-fold higher in NK cells and 11.7-fold in + T cells compared to the median across cell types. At the tissue level, TBX21 expression is predominant in lymphoid organs such as the spleen and lymph nodes, reflecting the abundance of T and NK cells, as well as in mucosal sites including the lung and small intestine, where it supports barrier immunity. According to GTEx data, median transcript levels (TPM) reach approximately 150-200 in whole blood, 100-150 in spleen, and 50-100 in lung and terminal ileum, underscoring its association with immune-rich environments. During inflammatory conditions, expression extends to non-immune tissues like the brain and skin, driven by infiltrating immune cells, with notable upregulation observed in neuroinflammatory models and psoriatic lesions. Developmentally, TBX21 displays low basal expression in embryonic stages, with limited detection in fetal immune precursors and early , primarily confined to neural tissues from embryonic day 14 in mice. Postnatally, expression upregulates in response to environmental antigens and infections, as evidenced by significantly lower levels (0.2-0.3-fold relative to adults) in neonatal T cells, which increase upon microbial exposure to support maturing adaptive immunity. In activated T cells, such as those stimulated , TBX21 transcripts are highly inducible, highlighting its role in postnatal immune responses.

Transcriptional and Post-Transcriptional Regulation

The expression of the TBX21 gene, encoding the T-bet, is primarily induced in T cells through IL-12 signaling, which activates STAT4 to bind conserved enhancer elements upstream of the gene. A key regulatory region approximately 13 kb upstream of the TBX21 transcription start site contains STAT4 binding sites that drive T-bet expression in response to IL-12, independent of IFN-γ/STAT1 signaling in + T cells. Similarly, IFN-γ signaling via contributes to TBX21 induction by binding to elements in the proximal promoter and upstream enhancers, such as a DNase I hypersensitive site around 3 kb upstream that becomes accessible during Th1 differentiation. Although direct binding of IRF1 and to the TBX21 promoter has been implicated in broader cytokine-responsive networks, their roles are more prominent in coordinating IL-12 receptor expression and auxiliary Th1 gene activation rather than direct TBX21 transactivation. In contrast, TBX21 expression is repressed in Th2 cells by transcription factors like Blimp-1 (encoded by ), which directly binds to the TBX21 locus to attenuate Th1 differentiation and reinforce Th2 commitment. GATA3, the master regulator of Th2 cells, similarly suppresses TBX21 by competing for shared distal regulatory elements and promoting Th2-specific , thereby limiting T-bet levels during Th2 polarization. Epigenetic silencing further reinforces this repression, with lysine 27 trimethylation () marking the TBX21 locus in Th2 cells to maintain a bivalent or repressive state, which is resolved to an active configuration (loss of and gain of ) upon Th1 differentiation. At the post-transcriptional level, microRNA-29a (miR-29a) targets the 3' (UTR) of TBX21 mRNA, reducing its stability and translation in helper T cells to fine-tune T-bet protein levels during differentiation. Additionally, TBX21 participates in a positive feedback loop where T-bet induces IFN-γ production, and the resulting IFN-γ signaling further upregulates TBX21 expression via , sustaining Th1 commitment.

Physiological Roles

Role in Adaptive Immunity

TBX21 encodes the T-bet, which plays a pivotal role in directing the differentiation of CD4+ T helper (Th) cells toward the Th1 lineage within adaptive immunity. T-bet is induced by signals such as IL-12 and IFN-γ, leading to its binding to the Ifng promoter and enhancer regions, thereby driving robust expression of interferon-gamma (IFN-γ), a hallmark of Th1 cells.80702-7) This activation promotes the development of Th1 effector functions essential for against intracellular pathogens. Simultaneously, T-bet represses alternative Th lineages by directly binding to regulatory elements of Th2-associated genes like Il4 and inhibiting their transcription through recruitment of repressors such as Bcl-6. T-bet also suppresses Th17 differentiation by interacting with Runx1 to repress RORγt expression and by directly repressing , thereby preventing IL-17 production and maintaining Th1 commitment. In + T cells, T-bet similarly orchestrates cytotoxic effector functions critical for adaptive antiviral responses. Upon antigen stimulation, T-bet expression promotes the upregulation of genes encoding , perforin, and IFN-γ, enabling target cell lysis and clearance of virus-infected cells. This regulation is essential for the terminal differentiation of effector + T cells during acute infections, such as with lymphocytic choriomeningitis virus (LCMV). Furthermore, T-bet cooperates with the related factor Eomesodermin to balance effector and memory + T cell fates; high T-bet levels favor short-lived effectors, while balanced expression supports the generation of long-lived memory cells capable of secondary responses. These mechanisms ensure robust + T cell-mediated control of and persistence. T-bet indirectly influences responses in adaptive immunity by driving Th1-derived IFN-γ production, which promotes class switching to IgG2a in mice, enhancing opsonization and complement against pathogens.80702-7) This IFN-γ-dependent pathway supports humoral contributions to Th1-biased immunity, particularly in infections requiring both cellular and antibody-mediated clearance. Studies using Tbet-/- mice have underscored these roles, revealing profound defects in Th1 responses. These mice exhibit impaired IFN-γ production and a Th2 bias, rendering them highly susceptible to Leishmania major infection, where they fail to resolve cutaneous lesions due to inadequate Th1-mediated . Similarly, CD8+ T cell and antiviral control are compromised in the absence of T-bet, highlighting its non-redundant function in adaptive T cell immunity.

Role in Innate Immunity and Mucosal

TBX21, encoding the transcription factor , plays a pivotal role in innate immune responses by directing the function of natural killer (NK) cells and dendritic cells (DCs). In NK cells, T-bet governs the expression of perforin and interferon-gamma (IFN-γ), essential effectors for against viral infections and tumor cells.31453-7) T-bet deficiency impairs NK cell maturation and IFN-γ production, leading to reduced antiviral and anti-tumor activity. In DCs, T-bet promotes the production of IL-12 family cytokines, including IL-12p70, IL-23, and IL-27, which bridge innate and adaptive immunity by activating downstream signaling in T cells and NK cells. Ectopic T-bet expression in DCs enhances their capacity to drive type 1 immune responses, underscoring its regulatory influence on innate . In mucosal , T-bet maintains barrier integrity at sites like the gut and lungs through its actions in intraepithelial lymphocytes (IELs) and group 3 (ILC3s). Within IELs, T-bet enforces a balance between IL-17 and IFN-γ production, suppressing excessive IL-17 to prevent while supporting IFN-γ-mediated pathogen surveillance. T-bet-expressing IELs, including ILC1-like subsets, contribute to epithelial by producing IFN-γ in response to microbial cues.30291-6) In ILC3s, T-bet controls cellularity and functional plasticity, modulating the transition toward IFN-γ-producing ILC1-like cells that aid in tissue repair and inflammation resolution. By regulating RORγt expression in ILC3s, T-bet ensures appropriate IL-22 output, which promotes epithelial regeneration without unchecked proliferation. T-bet supports mucosal barrier integrity by suppressing hyper while facilitating clearance, as evidenced by studies in T-bet-deficient models. In the absence of T-bet, innate immune dysregulation leads to increased epithelial permeability and spontaneous in mice, characterized by barrier breaches and microbiota-driven . These mice exhibit heightened TNF-α from colonic DCs and impaired , resulting in transmissible disease resembling human . T-bet thus enables balanced responses that clear pathogens without compromising tissue structure, particularly in the gut where it coordinates innate effector functions. T-bet facilitates crosstalk between the and through regulation of antimicrobial defenses, including Reg3g peptides produced by epithelial cells. In ILC3s, T-bet modulates IL-22 signaling, which induces Reg3g expression to limit bacterial overgrowth and maintain microbial composition. T-bet deficiency disrupts this axis, leading to and reduced Reg3g-mediated containment of , exacerbating susceptibility. This interaction highlights T-bet's role in sustaining symbiotic relationships at mucosal sites.

Pathological Implications

Role in Autoimmune and Inflammatory Diseases

TBX21, encoding the T-bet, plays a pivotal role in driving Th1-mediated inflammation in (MS), where its overexpression in CD4+ and CD8+ T cells correlates with disease activity and (CNS) inflammation. In relapsing-remitting MS patients, elevated T-bet expression in peripheral blood mononuclear cells promotes IFN-γ production by Th1 cells, exacerbating demyelination and axonal damage. Therapeutic interventions like glucocorticoids and IFN-β reduce T-bet levels in these cells, alleviating symptoms and correlating with improved clinical outcomes. Genetic evidence further supports this, with the TBX21 -1514T>C polymorphism conferring a protective effect against MS susceptibility in certain populations, likely by modulating Th1 differentiation. In experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, T-bet deficiency ameliorates disease severity, as T-bet-/- mice exhibit reduced CNS infiltration by encephalitogenic Th1 and Th17 cells, despite preserved IFN-γ-independent pathways. Dysregulated T-bet serves as a molecular subtype marker alongside EOMES. In inflammatory bowel disease (IBD), T-bet exerts a protective role in colitis through regulation of mucosal immunity, but its dysregulation contributes to pathogenesis in Crohn's disease. T-bet governs functional maturation of intraepithelial lymphocytes (IELs), promoting CD8αα+ IEL development and epithelial barrier integrity; reduced T-bet expression in IELs from Crohn's patients leads to barrier leakiness, increased microbial translocation, and heightened Th17 responses. In mouse models, T-bet overexpression in T cells induces Th1-driven colitis, while T-bet deficiency in innate lymphoid cells spontaneously triggers communicable ulcerative colitis-like inflammation, underscoring its context-dependent mucosal regulation. Conversely, T-bet-/- mice resist Th1-mediated colitis but succumb to Th2/Th17-driven forms, illustrating its bias toward type 1 immunity. TBX21 exhibits a dual role in and allergies, countering Th2 dominance in allergic forms while contributing to severity in others. In allergic , T-bet promotes Th1 differentiation to suppress IL-4 and IL-5 production, mitigating airway hyperresponsiveness; T-bet deficiency in mice exacerbates allergen-induced via unchecked Th2 cytokines. studies show lower T-bet in lung CD4+ T cells from asthmatics, with polymorphisms like rs2240017 linked to increased susceptibility and reduced responsiveness. In , an inflammatory , T-bet promotes pro-inflammatory responses indirectly by driving Th1 cytokines such as IFN-γ, which polarize macrophages toward an M1 state and contribute to plaque formation and instability. T-bet deficiency in Ldlr-/- mice reduces lesion size and shifts immune responses from Th1 to Th2, decreasing oxidized LDL-specific IgG2a antibodies and enhancing protective isotypes. This highlights T-bet's contribution to chronic vascular inflammation via innate and adaptive arms.

Role in Infectious Diseases and Cancer

TBX21, encoding the T-bet, plays a critical role in orchestrating protective immune responses against intracellular by promoting Th1 cell differentiation and IFN-γ production in CD4+ T cells and natural killer (NK) cells. In mouse models, T-bet deficiency leads to heightened susceptibility to infection, characterized by reduced IFN-γ secretion and increased IL-10 production, which impairs bacterial control. Similarly, human T-bet mutations disrupt NK cell and innate-like lymphocyte function, resulting in recurrent mycobacterial disease due to defective IFN-γ responses. While T-bet is dispensable for resolving infection in mice, it is essential for mounting effective cytotoxic responses against viruses such as virus (LCMV), where T-bet-deficient + T cells exhibit impaired effector function and fail to clear the . In cancer, T-bet exhibits context-dependent functions, acting as a tumor suppressor by enhancing anti-tumor immunity while also contributing to pro-tumor inflammation in certain settings. High TBX21 expression in skin cutaneous correlates with improved patient prognosis and activation of immunological pathways that bolster + T cell-mediated tumor control. Checkpoint blockade efficacy in melanoma models relies on T-bet expression in tumor-draining lymph nodes to promote cytotoxic + T cell responses. Conversely, T-bet in regulatory T cells (Tregs) can suppress anti-tumor immunity; T-bet+ Tregs accumulate in oropharyngeal cancers and inhibit effector T cell function through type 1 responses. In gastric cancer, tumor infiltration by T-bet+ effector T cells is associated with better survival, yet the IL-12/T-bet axis can drive chronic inflammation that indirectly supports tumor progression in IL-12-rich microenvironments. Therapeutically, strategies to enhance T-bet activity, such as adjuvants that induce T-bet-dependent IL-12 production, have been explored to boost anti-viral efficacy by promoting Th1-biased responses. In cancer models, T-bet overexpression in adoptively transferred cells reduces tumor burden; for instance, combined T-bet and ZEB2 overexpression in mouse models significantly decreases tumor growth and extends survival independent of PD-1 blockade. Lower TBX21 expression in various cancers, including lung adenocarcinoma, correlates with poor , highlighting its potential as a , though specific data remain limited. Targeting excessive Th1-driven responses via indirect T-bet modulation, such as farnesyltransferase inhibitors like tipifarnib that suppress T-bet and Th1 production, shows promise in Th1-associated malignancies like large granular .

References

  1. https://omim.org/entry/604895
  2. https://doi.org/10.1016/s0092-8674(00)80702-3
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC6290922/
  4. https://doi.org/10.1006/geno.2000.6361
  5. https://immunityageing.biomedcentral.com/articles/10.1186/s12979-023-00385-1
  6. https://doi.org/10.1038/nri3536
  7. https://doi.org/10.4049/jimmunol.180.12.8004
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC6290474/
  9. https://doi.org/10.4049/jimmunol.175.7.4593
  10. https://doi.org/10.1016/j.cell.2020.10.046
  11. https://doi.org/10.1172/JCI26631
  12. https://doi.org/10.1084/jem.20082584
  13. https://doi.org/10.1126/science.1065544
  14. https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000073861
  15. https://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000073861;t=ENST00000177694
  16. https://www.ncbi.nlm.nih.gov/gene/30009
  17. https://www.researchgate.net/figure/Structure-and-protein-modification-of-T-bet-Mouse-and-human-T-bet-is-100-identical-in_fig1_262886239
  18. https://www.uniprot.org/uniprotkb/Q9UL17/entry
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC2988494/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC2227921/
  21. https://www.pnas.org/doi/10.1073/pnas.1613914113
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC3273642/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC4036734/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC8175150/
  25. https://www.nature.com/articles/ni1268
  26. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.00606/full
  27. https://www.genecards.org/cgi-bin/carddisp.pl?gene=TBX21
  28. https://www.proteinatlas.org/ENSG00000073861-TBX21/tissue
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC7325556/
  30. https://gtexportal.org/home/gene/TBX21
  31. https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-024-03144-1
  32. https://www.sciencedirect.com/science/article/pii/S2211124717303637
  33. https://onlinelibrary.wiley.com/doi/full/10.1002/eji.201141847
  34. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1128423/full
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC3077962/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC3858236/
  37. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2016.00241/full
  38. https://www.sciencedirect.com/science/article/pii/S1074761304000767
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC2921905/
  40. https://academic.oup.com/jimmunol/article-abstract/183/11/7250/8053399
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC4287410/
  42. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.623324/full
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC6597213/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC2169385/
  45. https://www.sciencedirect.com/science/article/pii/S1074761312004219
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC4799884/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC4682364/
  48. https://www.jci.org/articles/view/62236
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC6420692/
  50. https://rupress.org/jem/article/206/7/1549/40340/T-bet-is-essential-for-encephalitogenicity-of-both
  51. https://pubmed.ncbi.nlm.nih.gov/24495857/
  52. https://pubmed.ncbi.nlm.nih.gov/17923086/
  53. https://pubmed.ncbi.nlm.nih.gov/11994418/
  54. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1005913
  55. https://www.pnas.org/doi/10.1073/pnas.0408532102
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC547865/
  57. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1461535/full
  58. https://pubmed.ncbi.nlm.nih.gov/16177104/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC7770098/
  60. https://pubmed.ncbi.nlm.nih.gov/15528324/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC307651/
  62. https://pubmed.ncbi.nlm.nih.gov/32561704/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC12594841/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC4612510/
Add your contribution
Related Hubs
User Avatar
No comments yet.